Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first episode psychotic and chronic schizophrenia in patients

Turk Psikiyatri Dergisi

Volumn 17, Issue 2, 2006, Pages

  Başoǧlu, Cengiz ^a   Çetin, Mesut ^a   Ömer, Özgür ^a   Ebrinç, Servet ^a   Başer, Ümit ^a   Kandilcioǧlu, Hamdi ^a   Şilit, Emir ^a   Kizilkaya, Efreş ^a  

^a NONE

Author keywords

First episode; Magnetic Resonance Spectroscopy; Schizophrenia; Temporal lobe; Thalamus

Indexed keywords

EID: 33745202049     PISSN: 13002163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Andreasen NC (1983) Scale for the Assessment of Positive Symptoms (SAPS) Iowa City, University of Iowa.
2. Andreasen NC (1984) Scale for the Assessment of Negative Symptoms (SANS) Iowa City, University of Iowa.
3. Auer DP, Wilke M, Grabner A et al. (2001) Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res, 52:87-99.
4. Bartha R, al-Semaan YM, Williamson PC et al. (1999) A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry, 45:1403-11.
5. Bertolino A, Sciota D, Brudaglio F et al. (2003) Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry, 160:483-9.
6. Bertolino A, Weinberger DR (1999) Proton magnetic resonance spectroscopy in schizophrenia. Eur J Radiol, 30:132-41.
7. Bertolino A, Callicott JH, Elman I et al. (1998) Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry, 43:641-8.
8. Bertolino A, Nawroz S, Mattay VS et al. (1996) Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry, 153:1554-63.
9. Block W, Baye TA, Tepest R et al. (2000) Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett, 289:147-51.
10. Bustillo JF, Lauriello J, Rowland LM et al. (2002) Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Sch Res, 58:313-21.
11. Bustillo JR, Rowland LM, Lauriello J et al. (2002) High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia. Am J Psychiatry, 159:130-3.
12. Deicken RF, Feiwell R, Schuff N et al. (2001) Evidence for altered cerebellar vermis neuronal integrity in schizophrenia. Psychiatry Res, 107:125-34.
13. Deicken RF, Zhou L, Schuff N et al. (1998) Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry, 43:483-8.
14. Delamillieure, P., Constans, J.M., Fernandez, J. et al. (2002) Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr Bull, 28:329-39.
15. DeLisi, L.E., Sakuma, M., Maurizio, A.M ve ark (2004) Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Res, 130:57-70.
16. Ende G, Braus DF, Walter S, Henn FA (2001) Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia: a replication study. Am J Psychiatry, 158:1314-6.
17. Ende G, Braus DF, Walter S et al. (2000) Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr Res, 41:389-95.
18. Erkoç, Ş, Arkonaç O, Atakli C et al. (1991a) Validity and reliability of the Scale For Assessment of Negative Symptoms (SANS). Düşünen Adam, 4:14-19.
19. Erkoç, Ş, Arkonaç O, Atakli C (1991b) Validity and reliability of the Scale For Assessment of Positive Symptoms (SAPS). Düşünen Adam, 4:20-24.
20. First MB, Spitzer RL, Gibbon M et al. (1997) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, D.C. American Psychiatric Press.
21. Fukuzako H, Fukuzako T, Hashiguchi T et al. (1999b) Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients Am J Psychiatry, 156:1205-8.
22. Fukuzako H, Fukazako T, Takeuchi K et al. (1996) Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry, 20:629-40.
23. Fukuzako H, Kodama S, Fukuzako T ve ark (1999a) Subtype-associated metabolite differences in the temporal lobe in schizophrenia detected by proton magnetic resonance spectroscopy. Psychiatry Res, 92:45-56.
24. Fukuzako H, Takeuchi K, Hokazono Y et al. (1995) Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Research. 61:193-200.
25. Gimenez M, Junque C, Perez M et al. (2003) Basal ganglia N-acetylaspartate correlates with the performance in theprocedural task 'Tower of Hanoi' of neuroleptic-naive schizophrenic patients. Neurosci Lett, 347:97-100.
26. Guy W (1976) ECDEU Assessment manual for psychopharmacology. Rockville, MD: US Department of Health and Human Services publication (ADM) s.218-22.
27. Guze BH (1991) Magnetic resonance spectroscopy. A technique for functional brain imaging. Arch Gen Psychiatry. 48:572-4.
28. Hagino H, Suzuki M, Mori K et al. (2002) Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patientswith schizophrenia: a preliminary report. Psychiatry Clin Neurosci, 56:499-507.
29. Heinz A, Romero B, Gallinat J et al. (2003) Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry, 36:152-157.
30. Jensen JE, Miller J, Williamson PC et al. (2004) Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: (31)P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry, 184:409-415.
31. Kegeles LS, Shungu DC, Anjilvel S et al. (2000) Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res, 98:163-75.
32. Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? Evidence from clinical and neurobiological perspective. Biol Psychiatry, 46:729-39.
33. Maier M, Mellers J, Toone B et al. (2000) Schizophrenia, temporal lobe epilepsy and psychosis: an in vivo magnetic resonance spectroscopy and imaging study of the hippocampus/amygdala complex. Psychol Med, 30:571-81.
34. Maier M, Ron MA, Barker GJ et al. (1995) Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med, 25:1201-9.
35. Moffett JR, Namboodiri MA (1995) Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol, 24:409-33.
36. Nasrallah HA, Skinner TE, Schmalbrock P et al. (1994). Proton magnetic resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiatry, 165:481-5.
37. Omori M, Murata T, Kimura H et al. (2000) Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res, 98:155-62.
38. O'Neill J, Levitt J, Caplan R et al. (2004) 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage, 21:1781-9.
39. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychological Reports. 10:799-812.
40. Rubin Y, LaPlaca MC, Smith DH et al. (1995) The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neurosci Lett, 198:209-12.
41. Sigmundsson T, Maier M, Toone BK et al. (2003) Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res, 64:63-71.
42. Soykan C (1989) Institutional differences and case typicality as related to diagnosis system severity, prognosis and treatment. Master thesis, Middle East Technical University, Ankara.
43. Stanley JA, Williamson PC, Drost DJ et al. (1996) An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull, 22:597-609.
44. Theberge J, Al-Semaan Y, Williamson PC et al. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry, 160:2231-3.
45. Vance AL, Velakoulis D, Maruff P et al. (2000) Magnetic resonance spectroscopy and schizophrenia: what have we learnt? Aus NZ J Psychiatry, 34:14-25.
46. Wood SJ, Berger G, Velakoulis D et al. (2003) Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull, 29:831-43.
47. Yamasue H, Fukui T, Fukuda R et al. (2002) 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport. 13:2133-7.
48. Yurgelun-Todd DA, Renshaw PF, Gruber SA et al. (1996) Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res, 19:55-9.